Printer Friendly

EVRO FINANCIAL TO ACQUIRE COMPUTER-AIDED LASER SCANNING UNIT AND PROPRIETARY SOFTWARE FROM DYNAMED TECHNOLOGIES

 TAMPA, Fla., April 9 /PRNewswire/ -- D. Jerry Diamond, chairman/CEO of EVRO Financial Corp. (NASDAQ: EVRO), announced today that EVRO has signed an agreement to acquire a computer-aided laser scanning unit and proprietary software from DynaMed Technologies, Inc., a privately held research and development company. This technology will be used by EVRO's wholly owned subsidiary, Lintronics Technologies, Inc., to enhance its laser imaging technology, the MAMMO-SCAN(R). Through these additional computer software and digital enhancements, the MAMMO-SCAN(R) will offer detailed images of soft body parts in general and breast tissue in particular. It is the company's opinion that the MAMMO- SCAN(R) will, after obtaining regulatory approvals, offer a safe, effective and welcome addition to the other highly advanced imaging modality for breast evaluation, magnetic resonance imaging (MRI), but at a much lower cost to both physician and patient.
 "This technology purchase will enable the company to prepare units for field studies and clinical evaluation," stated Diamond, "thereby accelerating the time table in which the technology can be tested for ultimate sale to the public. At a time when the public is demanding safe and effective breast examination options that do not expose the patient to ionizing radiation, it is our belief that the MAMMO-SCAN(R) may one day become the modality of choice as the primary screening modality for breast cancer, and it is our goal to make those options available to the medical community and the patients they serve."
 Unrelated to this announcement, the company learned that a breast imaging center in Illinois had a LINTRO-SCAN(R) seized by the FDA for alleged misbranding. The LINTRO-SCAN(R) is a transillumination product manufactured by Lintronics. Neither the company nor its subsidiary have been named as a party in any action by the U.S. Food and Drug Administration. The company is taking steps to continue dialogue with the FDA in an attempt to resolve labeling issues regarding the LINTRO- SCAN(R).
 Diamond noted, "Once all the facts are reviewed, we anticipate no negative impact from this seizure. We remain strong advocates of transillumination and its adjunctive role in the breast evaluation process."
 -0- 4/9/93
 /CONTACT: D. Jerry Diamond, chairman and CEO, or Dominick R. Maggio, vice president of public relations of EVRO Financial Corp., 813-623-6044/
 (EVRO)


CO: EVRO Financial Corp.; Lintronics Technologies, Inc.; DynaMed
 Technologies, Inc. ST: Florida IN: HEA SU: TNM


AW-JJ -- FL005 -- 4576 04/09/93 15:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 9, 1993
Words:405
Previous Article:RETIRED NORFOLK SOUTHERN CHAIRMAN/CEO DIES
Next Article:MEDTRONIC BOARD APPROVES THREE-MILLION-SHARE STOCK REPURCHASE PROGRAM
Topics:


Related Articles
EVRO FINANCIAL ANNOUNCES LETTER OF INTENT
EVRO FINANCIAL ANNOUNCES ACQUISITION
LINTRONICS TECHNOLOGIES SIGNS A-MED AS MEDICAL EQUIPMENT DEALER FOR SALE OF PRODUCTS
AMERICAN CLINICAL LABS SIGNS AGREEMENT WITH WESTCAP EQUITY MANAGEMENT
EVRO FINANCIAL SUBSIDIARY ANNOUNCES HEIGHTENED INTEREST IN ADVANCED BREAST EXAMINATION TECHNOLOGIES
LaserSight Participates in First Customized Ablation Study Conducted With the LaserScan Excimer Laser System.
DYNAMED'S MEDICAL COMPRESSION DEVICE INCREASES MRI/CT ACCURACY.
LaserSight Receives Scanning Patent For Smooth And Uniform Ablation.
LaserSight CEO Discusses Patents and the Industry's Future.
Wireless patient registration.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters